For most of my career, finasteride wasn’t a hair loss medication.

It was a prostate medication.

We’ve prescribed it for decades to men with enlarged prostates, and it’s one of the most effective medications we have.

It shrinks the prostate over time, improves urinary symptoms, lowers the risk of urinary retention, and significantly reduces the chance that a man will eventually need surgery.

It’s a good drug.

I still prescribe it regularly.

One unexpected bonus was that many men noticed they stopped losing hair. Some even joked they could pee better and keep the hair they still had.

That’s largely what finasteride does—it helps preserve existing hair more than it grows new hair.

We’ve also known for years that some men develop sexual side effects while taking it.

Reduced libido, erectile dysfunction, and changes in ejaculation have never been secrets.

Those risks have always been part of the prescribing conversation.

So what’s changed?

Not the drug.

The conversation.

Today, many of the men taking finasteride aren’t in their sixties trying to avoid prostate surgery.

They’re in their twenties or thirties trying to keep their hair.

That changes the discussion.

A healthy young man taking 1 mg for hair loss is making a very different decision than a 68-year-old taking 5 mg for an enlarged prostate.

The medication is nearly the same.

The reason for taking it—and the trade-offs he’s willing to accept—are not.

The conversation has also expanded beyond side effects while taking the medication.

The FDA now includes post-marketing reports of persistent sexual dysfunction, along with depression and suicidal thoughts after discontinuation.

Some researchers believe these persistent effects are now well established.

Others argue the evidence cannot yet prove cause and effect, and that what has been called post-finasteride syndrome remains scientifically unsettled.

As physicians, we have to be comfortable sitting with that uncertainty.

I’ve also wondered whether part of the conversation reflects the changing patient as much as the medication.

A young man starting treatment for hair loss often has more at stake in terms of fertility, new relationships, sexual confidence, and decades of expected sexual function ahead of him.

The same side effect may be experienced very differently than it is by someone treating urinary symptoms later in life.

Whether that explains some of what we’re seeing isn’t clear—but it’s another reason these conversations deserve nuance.

Hair loss isn’t an all-or-nothing decision, either.

Minoxidil, whether topical or oral in appropriate patients, works through a completely different mechanism and isn’t known to affect sexual function.

It may not be as effective for every man, but for many it’s a reasonable first step or an alternative worth discussing.

So where do I land?

About where I’ve always been.

Finasteride is an excellent medication.

It has helped millions of men, whether they’re trying to avoid prostate surgery or slow hair loss, but good medications still deserve honest conversations.

That means acknowledging what we’ve known for years, being honest about what we’re still learning, and making sure every man understands the benefits, the uncertainties, and the trade-offs before he starts treatment.

We’re talking about informed consent, not fear, and I think our patients deserve nothing less.